PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer

Phase 3

Completed

Conditions: Kidney Neoplasms

Interventions: Drug: Axitinib (AG-013736)
Drug: Sorafenib

First Posted Date: 2008-05-15

Last Posted Date: 2019-01-09

Lead Sponsor: Pfizer

Target Recruit Count: 723

Registration Number: NCT00678392

Locations: 🇺🇸
LAC-USC Medical Center, Los Angeles, California, United States
🇺🇸
Ronald Regan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
USC Norris Cancer Hospital and Clinics, Los Angeles, California, United States

and more 231 locations

Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa

Phase 2

Completed

Conditions: Malaria, Falciparum

Interventions: Drug: Azithromycin plus Chloroquine
Drug: Artemether-lumefantrine

First Posted Date: 2008-05-15

Last Posted Date: 2014-06-26

Lead Sponsor: Pfizer

Target Recruit Count: 361

Registration Number: NCT00677833

Locations: 🇲🇱
Pfizer Investigational Site, Sikasso, West Africa, Mali

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Phase 2

Withdrawn

Conditions: Breast Cancer

Interventions: Drug: CP-751,871
Drug: Docetaxel

First Posted Date: 2008-05-15

Last Posted Date: 2015-05-04

Lead Sponsor: Pfizer

Registration Number: NCT00678626

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: CP-690,550
Drug: Placebo

First Posted Date: 2008-05-15

Last Posted Date: 2012-12-19

Lead Sponsor: Pfizer

Target Recruit Count: 197

Registration Number: NCT00678210

Locations: 🇨🇦
Pfizer Investigational Site, Quebec, Canada

Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections

Phase 1

Completed

Conditions: Bacterial Infections

Interventions: Drug: Dalbavancin

First Posted Date: 2008-05-15

Last Posted Date: 2009-10-12

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT00678106

Locations: 🇺🇸
Pfizer Investigational Site, Cleveland, Ohio, United States

Topical CP-690,550 For Chronic Plaque Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: CP-690,550
Drug: Placebo Vehicle

First Posted Date: 2008-05-15

Last Posted Date: 2020-12-31

Lead Sponsor: Pfizer

Target Recruit Count: 81

Registration Number: NCT00678561

Locations: 🇨🇦
NewLab Clinical Research Inc., St. John's, Newfoundland and Labrador, Canada
🇺🇸
Central Dermatology, PC, Saint Louis, Missouri, United States
🇺🇸
Dermatology Consulting Services, High Point, North Carolina, United States

and more 17 locations

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

Phase 3

Terminated

Conditions: Prostatic Neoplasms

Interventions: Drug: Placebo
Drug: Prednisone
Drug: sunitinib

First Posted Date: 2008-05-13

Last Posted Date: 2013-03-08

Lead Sponsor: Pfizer

Target Recruit Count: 873

Registration Number: NCT00676650

Locations: 🇬🇧
Pfizer Investigational Site, Swansea, United Kingdom

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

Phase 3

Terminated

Conditions: Alzheimer Disease

Interventions: Drug: bapineuzumab
Drug: placebo

First Posted Date: 2008-05-12

Last Posted Date: 2016-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 1100

Registration Number: NCT00676143

Locations: 🇺🇸
UPENN Clinical and Transitional Research Center, Philadelphia, Pennsylvania, United States
🇺🇸
Texas Neurology, P.A., Dallas, Texas, United States
🇺🇸
Compass Research, LLC, Orlando, Florida, United States

and more 275 locations

Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer

Phase 3

Terminated

Conditions: Carcinoma, Adenosquamous Cell
Carcinoma, Squamous Cell
Carcinoma, Large Cell
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: CP 751,871 (Figitumumab)
Drug: Erlotinib

First Posted Date: 2008-05-07

Last Posted Date: 2013-07-24

Lead Sponsor: Pfizer

Target Recruit Count: 583

Registration Number: NCT00673049

Locations: 🇬🇧
Pfizer Investigational Site, Manchester, United Kingdom

Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

Phase 1

Completed

Conditions: Hepatitis, Chronic
Hepatitis C Virus

Interventions: Drug: Small Molecule Agent (PF-868554)

First Posted Date: 2008-05-05

Last Posted Date: 2014-01-14

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT00671671

Locations: 🇺🇸
Pfizer Investigational Site, Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy